The figure displays a schematic representation of the model developed for the analysis of LGG tumor size measurements.
P denotes the density of proliferative tissue, and Q the density of quiescent tissue that can become DNA-damaged (denotes Qp) due to the effect of the chemotherapy. The sum + + , calculating by solving the system of ordinary differential equations presented above was directly compared to the measured MTD in patients to estimate the typical value of model parameters.
We modeled the pharmacokinetics of the PCV chemotherapy using a kinetic-pharmacodynamic approach, in which drug concentration is assumed to decay according to an exponential function [1] . In the model, we did not consider the 3 drugs separately. Rather, we assumed the treatment to be represented as a whole by a unique variable ( ), which represents the concentration of a virtual drug encompassing the 3 chemotherapeutic components of the PCV regimen. We modeled the exact number of treatment cycles administered by setting the value of C to 1 (arbitrary unit) at the initiation of each cycle : ( = ) = 1. As a result, not the exact dose of PCV chemotherapy was integrated but the exact time (scheduling) of PCV administration was.
The model is composed by 8 parameters to be estimated including 2 initial conditions (initial estimates of the size of both proliferative and quiescent tissue). The model parameters were described by random variables (mixed-effect or population approach [2] ) to characterize the variability observed in MTD growth and response to treatment in the population of patients.
Variability was assumed on all model parameters except the KPD parameter related to the kinetic of drug concentration in plasma. Individual parameters were log-normally distributed, estimated for radiotherapy and temozolomide (see [3] for further details 
